drugset
drugset / Trial / NCT00191386

Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)

NCT00191386 ↗

Phase 3 Completed 228 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study is long-term extension study to evaluate long-term safety and efficacy of Atomoxetine in Japanese pediatric patients with Attention-Deficit/Hyperactivity Disorder (AD/HD).

Timeline

Start
2005-05
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 1.8 mg/kg Oral

Indications

attention deficit-hyperactivity disorder